Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer treatment according to BRCA1 and BRCA2 mutations.

Nature reviews. Clinical oncology - 1 Sept 2012

Maxwell Kara N, Domchek Susan M

Abstract excerpt

Identification of germline mutations associated with significant cancer susceptibility has the potential to change all aspects of an individual's care, from screening to cancer treatment. For example, women with germline mutations in BRCA1 and BRCA2 have markedly elevated risks of breast and ovar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 gene

Share to Mutation

Share to Uterine Neoplasms

Share to Women's Health

Source

Identifiers

PMID: 22825375
DOI: 10.1038/nrclinonc.2012.123

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22825375-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer treatment according to BRCA1 and BRCA2 mutations.PMID 22825375Read ↗

New Therapeutic Options for BRCA Mutant PatientsSemantic proximity Read ↗

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and BeyondSemantic proximity Read ↗

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Semantic proximity Read ↗

Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Semantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid TumorsSemantic proximity Read ↗

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.Semantic proximity Read ↗

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.Semantic proximity Read ↗

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.